<DOC>
	<DOC>NCT01715779</DOC>
	<brief_summary>The objective of this observational study is to characterize long-term (5 years post event) clinical outcomes in patients who experienced a thromboembolic event (TEE) during participation in the GSK ENABLE clinical trials. Patients eligible for the study are patient who experienced a TEE during participation in the ENABLE trials. Each included patient will be followed for a period of 5 years from the date of their first TEE. Demographic and clinical characteristics will be collected for the index date (time of TEE) and every sixth month during the follow-up period, information will be collected for the outcomes of interests: mortality, new TEE, hepatic decompensation, evaluation for liver transplant and result of evaluation, and liver transplantation. All information will collected by medical record review.</brief_summary>
	<brief_title>Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<criteria>Patients with portal vein thrombosis (PVT) Patients with deep vein thrombosis (DVT) Patients with pulmonary embolism (PE) Patients with myocardial infarction (MI) Patients with unstable angina Patients with transient ischemic attack (TIA) Patients with ischemic stroke Patients with other TEE including embolism, thrombosis, phlebitis, and thrombophlebitis at other locations There are no exclusion criteria for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>ENABLE</keyword>
	<keyword>observational</keyword>
	<keyword>mortality</keyword>
	<keyword>Thromboembolic Events</keyword>
	<keyword>Hepatic decompensation</keyword>
	<keyword>Long-Term follow-up</keyword>
	<keyword>TEE</keyword>
</DOC>